Enhanced potency of the polymeric fluoropyrimidine CF10 to KRAS-mutant colorectal cancer cells

被引：0
|
作者：
Gmeiner, William H. [1 ]
Manandhar, Mandira [1 ]
Hinds, Amanda M. [1 ]
Holmes, Julija [1 ]
Vidi, Pierre [1 ]
Tsunoda, Toshiyuki [2 ]
Shirasawa, Senji [2 ]
机构：
[1] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA
[2] Fukuoka Univ, Fac Med, Fukuoka, Fukuoka, Japan
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-2079
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2079
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Enhanced Therapeutic Efficacy of the Nanoscale Fluoropyrimidine Polymer CF10 in a Rat Colorectal Cancer Liver Metastasis Model
    Okechukwu, Charles Chidi
    Ma, Xue
    Sah, Naresh
    Mani, Chinnadurai
    Palle, Komaraiah
    Gmeiner, William H.
    CANCERS, 2024, 16 (07)
  • [2] Genetic modifiers of KRAS-mutant colorectal cancer
    Tjader, Nijole P.
    Ramroop, Johnny
    Gandhi, Tanish
    Campbell, Peter T.
    Chan, Andrew T.
    Gallinger, Steven
    Giles, Graham G.
    Gunter, Marc J.
    Harrison, Tabitha A.
    Hoffmeister, Michael
    Newcomb, Polly A.
    Ogino, Shuji
    Phipps, Amanda I.
    Qu, Conghui
    Schoen, Robert E.
    Pellatt, Andrew
    Woods, Michael O.
    Van Guelpen, Bethany
    Stevens, Patrick
    Hampel, Heather
    Peters, Ulrike
    McElroy, Joseph P.
    Toland, Amanda E.
    CANCER RESEARCH, 2024, 84 (06)
  • [3] Dasatinib sensitizes KRAS-mutant colorectal cancer tumors to cetuximab
    Lisa Hutchinson
    Nature Reviews Clinical Oncology, 2011, 8 (4) : 193 - 193
  • [4] Improved Antitumor Activity of the Fluoropyrimidine Polymer CF10 in Preclinical Colorectal Cancer Models through Distinct Mechanistic and Pharmacologic Properties
    Gmeiner, William H.
    Dominijanni, Anthony
    Haber, Alex O.
    Ghiraldeli, Lais P.
    Caudell, David L.
    D'Agostino, Ralph, Jr.
    Pasche, Boris C.
    Smith, Thomas L.
    Deng, Zhiyong
    Kiren, Sezgin
    Mani, Chinnadurai
    Palle, Komaraiah
    Brody, Jonathan R.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (03) : 553 - 563
  • [5] Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer
    Zhong, Longhui
    Wang, Rong
    Wang, Yanxia
    Peng, Shunli
    Ma, Yueyun
    Ding, Sijie
    Yang, Hong
    Chen, Shiyu
    Luo, Xiaoqing
    Wang, Wei
    NEOPLASIA, 2020, 22 (09): : 365 - 375
  • [6] Bromelain effectively suppresses Kras-mutant colorectal cancer by stimulating ferroptosis
    Park, Sujeong
    Oh, Jinjoo
    Kim, Minhee
    Jin, Eun-Jung
    ANIMAL CELLS AND SYSTEMS, 2018, 22 (05) : 334 - 340
  • [7] PCSK9 IS A THERAPEUTIC TARGET IN KRAS-MUTANT COLORECTAL CANCER
    Wong, Chi Chun
    Wu, Jianlin
    Chan, Lam-Shing
    Ji, Fenfen
    Kang, Wei
    To, Ka Fai
    Sung, Joseph J.
    Yu, Jun
    GASTROENTEROLOGY, 2021, 160 (06) : S64 - S64
  • [8] The polymeric fluoropyrimidine CF10 overcomes limitations of 5-FU in pancreatic ductal adenocarcinoma cells through increased replication stress
    Finan, Jennifer M.
    Di Niro, Roberto
    Park, Soon Young
    Jeong, Kang Jin
    Hedberg, Madeline D.
    Smith, Alexander
    Mccarthy, Grace A.
    Haber, Alex O.
    Muschler, John
    Sears, Rosalie C.
    Mills, Gordon B.
    Gmeiner, William H.
    Brody, Jonathan R.
    CANCER BIOLOGY & THERAPY, 2024, 25 (01)
  • [9] The polymeric fluoropyrimidine CF10 overcomes limitations of 5-FU in pancreatic ductal adenocarcinoma cells through increased replication stress
    DiNiro, Roberto
    Haber, Alex O.
    Jeong, Kang J.
    Park, Soon Y.
    Mills, Gordon B.
    Gmeiner, William H.
    Brody, Jonathan R.
    CANCER RESEARCH, 2022, 82 (12)
  • [10] ERK MAPK inhibition enhances the immunogenicity of KRAS-mutant colorectal cancer.
    Ryan, Meagan B.
    de la Cruz, Ferran Fece
    Ahronian, Leanne G.
    Phat, Sarah
    Myers, David T.
    Shahzade, Heather A.
    Hong, Catriona
    Corcoran, Ryan B.
    MOLECULAR CANCER RESEARCH, 2020, 18 (05) : 76 - 76
12345